These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 30215149)

  • 21. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus.
    Duan L; An X; Zhang Y; Jin D; Zhao S; Zhou R; Duan Y; Zhang Y; Liu X; Lian F
    Biomed Pharmacother; 2021 Oct; 142():112094. PubMed ID: 34449321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considering gut microbiota in treatment of type 2 diabetes mellitus.
    Adeshirlarijaney A; Gewirtz AT
    Gut Microbes; 2020 May; 11(3):253-264. PubMed ID: 32005089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
    Wu J; Yang K; Fan H; Wei M; Xiong Q
    Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiome and diabetes: Where are we now?
    Vallianou NG; Stratigou T; Tsagarakis S
    Diabetes Res Clin Pract; 2018 Dec; 146():111-118. PubMed ID: 30342053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus.
    Allin KH; Nielsen T; Pedersen O
    Eur J Endocrinol; 2015 Apr; 172(4):R167-77. PubMed ID: 25416725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.
    Sabatino A; Regolisti G; Cosola C; Gesualdo L; Fiaccadori E
    Curr Diab Rep; 2017 Mar; 17(3):16. PubMed ID: 28271466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unravelling the Role of Gut and Oral Microbiota in the Pediatric Population with Type 1 Diabetes Mellitus.
    Luppi S; Aldegheri L; Azzalini E; Pacetti E; Barucca Sebastiani G; Fabiani C; Robino A; Comar M
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Microbiome, diabetes and heart: a novel link?].
    Kappel BA; Lehrke M
    Herz; 2019 May; 44(3):223-230. PubMed ID: 30847506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gut microbiota and immune crosstalk in metabolic disease].
    Burcelin R
    Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microorganisms as promising targets for the management of type 2 diabetes.
    Delzenne NM; Cani PD; Everard A; Neyrinck AM; Bindels LB
    Diabetologia; 2015 Oct; 58(10):2206-17. PubMed ID: 26224102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes.
    Scheithauer TPM; Rampanelli E; Nieuwdorp M; Vallance BA; Verchere CB; van Raalte DH; Herrema H
    Front Immunol; 2020; 11():571731. PubMed ID: 33178196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interindividual variability in gut microbiota and host response to dietary interventions.
    Healey GR; Murphy R; Brough L; Butts CA; Coad J
    Nutr Rev; 2017 Dec; 75(12):1059-1080. PubMed ID: 29190368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut Microbiota and Gestational Diabetes Mellitus: A Review of Host-Gut Microbiota Interactions and Their Therapeutic Potential.
    Hasain Z; Mokhtar NM; Kamaruddin NA; Mohamed Ismail NA; Razalli NH; Gnanou JV; Raja Ali RA
    Front Cell Infect Microbiol; 2020; 10():188. PubMed ID: 32500037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders.
    Sankararaman S; Noriega K; Velayuthan S; Sferra T; Martindale R
    Curr Gastroenterol Rep; 2023 Feb; 25(2):31-44. PubMed ID: 36469257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
    Zhou Z; Sun B; Yu D; Zhu C
    Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut Microbiota and Their Associated Metabolites in Diabetes: A Cross Talk Between Host and Microbes-A Review.
    Safari-Alighiarloo N; Emami Z; Rezaei-Tavirani M; Alaei-Shahmiri F; Razavi S
    Metab Syndr Relat Disord; 2023 Feb; 21(1):3-15. PubMed ID: 36301254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin Sensitivity-Enhancing Activity of Phlorizin Is Associated with Lipopolysaccharide Decrease and Gut Microbiota Changes in Obese and Type 2 Diabetes (db/db) Mice.
    Mei X; Zhang X; Wang Z; Gao Z; Liu G; Hu H; Zou L; Li X
    J Agric Food Chem; 2016 Oct; 64(40):7502-7511. PubMed ID: 27635781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections.
    Serino M
    J Mol Biol; 2018 Mar; 430(5):581-590. PubMed ID: 29374557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.